What is the best treatment for hidradenitis suppurativa?

Best Treatment for Hidradenitis Suppurativa

The optimal treatment for hidradenitis suppurativa depends on disease severity (Hurley stage), with mild disease (Hurley I) responding to topical clindamycin and/or combination oral clindamycin-rifampin, moderate-to-severe disease (Hurley II-III) requiring biologic therapy with adalimumab or secukinumab as first-line systemic agents, and advanced disease necessitating combined medical-surgical approaches. 1, 2

Treatment Algorithm by Disease Severity

Hurley Stage I (Mild Disease)

• Start with topical clindamycin 1% solution applied to affected areas, which reduces pustules and improves patient self-assessment, though it has minimal effect on inflammatory nodules and abscesses 1
• Add antiseptic cleansers (chlorhexidine, benzoyl peroxide, or zinc pyrithione) to reduce bacterial colonization and potentially decrease clindamycin resistance 1
• For inadequate response, escalate to oral clindamycin 300 mg twice daily plus rifampin 300 mg twice daily for 8-12 weeks, which achieves response rates of 71-93% 1
• Consider intralesional triamcinolone 10 mg/mL (0.2-2.0 mL) for acute flares, which significantly reduces pain within 1 day and decreases erythema, edema, and suppuration 1

Hurley Stage II (Moderate Disease)

• Initiate biologic therapy with adalimumab (TNF-alpha inhibitor) or secukinumab (IL-17A inhibitor) as these are the only FDA-approved systemic treatments for moderate-to-severe HS 2, 3
• Combination oral clindamycin-rifampin can be used as adjunctive therapy or as a bridge to biologics, with response rates of 71-93% 1
• For refractory cases, consider the triple antibiotic regimen: moxifloxacin 400 mg once daily, metronidazole 500 mg three times daily (limited to 6 weeks to avoid neurologic toxicity), and rifampin 300 mg twice daily, which achieved complete response in 80% of Hurley II patients 1
• Surgery should be considered as adjuvant therapy for localized disease or scarring 4, 5

Hurley Stage III (Severe Disease)

• Biologic therapy is essential: adalimumab or secukinumab should be initiated early to prevent irreversible skin damage 6, 2, 3
• Bimekizumab (IL-17 inhibitor) represents a newer option in the expanding therapeutic pipeline 6
• Systemic antibiotics serve only as adjunctive therapy due to lower response rates and increased recurrence in advanced disease 1
• Surgical intervention is often necessary for definitive management of tunnels, scarring, and anatomical/functional mutilation 4, 5
• Pain management must be addressed as a primary outcome given the profound impact on quality of life 6, 5

Critical Considerations

Timing of Biologic Initiation

Early intervention with biologics prevents irreversible skin damage, tunnel formation, and morbid scarring that characterize the destructive phase of HS 6, 5. The pathogenesis involves complex innate immune mechanisms (IL-1β, TNF, granulocyte colony-stimulating factor), T-cell mechanisms (IL-17, IFN-γ), and B-cell mechanisms, making targeted immunomodulation crucial 6.

Common Pitfalls

• Tetracycline monotherapy (500 mg twice daily) showed only 30% reduction in abscesses with no significant patient-reported outcome improvements—avoid as monotherapy 1
• Doxycycline 100 mg twice daily was not independently linked to better outcomes when combined with adalimumab in PIONEER studies 1
• Topical clindamycin increases Staphylococcus aureus resistance rates; concurrent benzoyl peroxide may reduce this risk 1
• Resorcinol 15% cream, while effective for pain and abscess duration, frequently causes irritant dermatitis 1

Loss of Response

Patients may lose response to biologics over time 2. Therapeutic drug monitoring should be utilized to optimize treatment longevity and guide switching strategies between adalimumab and secukinumab 2.

Comorbidity Management

Screen for metabolic syndrome, inflammatory arthritis, and inflammatory bowel disease at diagnosis, as systemic inflammation drives these associations and requires interdisciplinary management 6, 4, 5.

Emerging Therapies

A robust pipeline of immunomodulatory drugs targeting various inflammatory pathways is in development, expanding future options beyond current TNF and IL-17 inhibitors 6, 3.